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ABSTRACT 
 
Pneumonia is a lung infection caused by bacteria with high fever symptoms accompanied by 
cough with phlegm, shortness of breath. According to Riskesdas 2013 results, the prevalence of 
pneumonia based on diagnosis at Yogyakarta Special Region is 1.7% and 4.6%. The researcher has 
founds 172 adult patients diagnosed pneumonia during 2011-2016 in PKU Muhammadiyah 
Yogyakarta hospital. This study aims to determine the level of effectiveness between 3
rd
 generation 
cephalosporins with 3
rd
 generation cephalosporins and macrolides on the outcome of adult patients 
with pneumonia in PKU Muhammadiyah Yogyakarta hospital period 2015-2017. It was a 
retrospective cohort study with an affordable population. There were two groups of 3
rd
 generation 
cephalosporins (n = 24) compared to the 3
rd
 generation cephalosporins and macrolide (n = 13) 
measured results in the form of body temperature, shortness of breath, leukocyte count, and length of 
hospitalization using univariate and bivariate analyzes. Based on the results of the study, 70.3% was 
dominated by men, and 51.4% was dominated by the age group > 59 years. Both of groups showed a 
significant difference to the temperature where p=0.001 with difference of temperature decrease 0.79 ± 
1.06 
o
C for single group while p=0.049 with difference of temperature decrease 0.65 ± 1.07 
o
C for 
combination group; as well as against leukocyte, both of groups had a value of p=0.001 where 
difference of leucocyte decrease was 4.80 ± 3.92 10
3
/mm
3
 for single group and 5.43 ± 4.27 10
3
 / mm
3
 
combination group. While both of group showed no significant difference for shortness of breath 
p=0.638 with OR (95% CI) 2.4 (0.23 – 24.06) and p=0.435 for hospitalization, in single group was 
5.88 ± 3.261 days while in combination group was 5.00 ± 1.826, this shows that the combination 
group had an average length of hospitalization of 0.88 days faster than the single group. The 
effectiveness between two groups showed a significant difference with p<0.05 on body temperature 
and leukocyte count. While both groups did not show a significant difference with p>0.05 to shortness 
of breath and length of stay. 
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INTRODUCTION 
Pneumonia is a lung infection caused by bacteria with high fever symptoms accompanied by 
cough with phlegm, rapid breathing (breathing frequency> 50 times per minute), shortness of breath, 
and other symptoms such as headache, anxiety and decreased appetite (Anonim, 2013). Most 
pneumonia is caused by microorganisms such as bacteria or viruses and a small part is caused by 
aspiration and radiation. In developing countries, pneumonia is caused by bacteria (Kamal, 2015). 
Common causes of pneumonia are typical bacteria, especially Streptococcus pneumonia, Haemophilus 
influenza, and Staphylococcus aureus. Pneumonia bacterial is generally responsive to treatment with 
beta-lactams, whereas those unresponsive to the beta-lactam group called atypical pneumonia (Said, 
2010). 
As big as 1% of adults have CAP annually. The diagnosis of adult patients with lower-
respiratory tract infections is 5-12%, and 22-24% of these diagnoses are hospitalized in the UK, where 
mortality ranges from 5% to 14%. As big as 1.2% to 10% of adult patients with pneumonia are 
hospitalized for intensive care, and for these patients the risk of death is greater than 30% (Woodhead, 
et al., 2014). 
Period prevalence in 2013 is 1.8 percent and 4.5 percent. The five provinces with the highest 
incidence and prevalence of pneumonia for all ages were East Nusa Tenggara at 4.6% and 10.3%, 
Papua 2.6% and 8.2%, Central Sulawesi 3.5% and 7.2% 3.1% and 6.1%, and South Sulawesi 2.8% and 
6.8% (Anonim, 2013). While the Special Region of Yogyakarta (DIY)  is  1.7% and 4.6% (Anonim, 
2013). Based on the population age group, the prevalence of high pneumonia occurs in the age group 1 
- 4 years, then begins to increase at age 45 - 54 years and continues to increase in the next age group 
(Anonim, 2013). 
Preliminary study on the patients with pneumonia (J18.9) conducted by researchers 
retrospectively in 2011 - 2016 in hospital PKU Muhammadiyah Yogyakarta as many as 172 adult 
inpatients. A total of 110 is dominated by men while 62 are female patients. The study is expected to 
provide information on the use of antibiotics to the outpatient of pneumonia therapy of adult patients at 
the hospital inpatient installation PKU Muhammadiyah Yogyakarta and increase the active role of 
pharmaceutical practitioners in monitoring and evaluating the use of antibiotics to the outcome of 
pneumonia patient therapy. 
 
MATERIAL AND METHODS 
Instruments and samples 
This study used a retrospective cohort design. The data were taken from medical record at 
hospital medical unit of PKU Muhammadiyah Yogyakarta period 2015 until 2017 with the number of 
affordable population as many as 37 CAP patients with total sampling methodes. Supporting data in 
this research are name, age, gender, antibiotic usage data (name, dose, frequency, duration), diagnostic 
data from doctor in charge including examination of body temperature, shortness of breath, leukocyte 
count, and length of stay. 
The data were taken according to the inclusion criteria which included (1) ≥18 patients with 
diagnosed community acquired pneumonia ICD (J1.9) who was admitted to hospital PKU 
Muhammadiyah Yogyakarta. (2) patients receiving either a 3
rd
-generation or single-cephalosporin 
antibiotic therapy combination with macrolide for at least 72 hours (Bradley, et al., 2011). (3) CAP 
patients with leukocytosis (>10/mm3) adjusted the standard laboratory values of PKU Muhammadiyah 
Yogyakarta hospital. While for the exclusion criteria are: (1) the patient is declared to be forced or 
died (before 72 hours / three days of therapy with cephalosporin 3
rd
 generation single or combination 
with macrolide) in the hospital treatment  
PKU Muhammadiyah Yogyakarta. (2) patients with other infections. (3) patients with 
immunosuppressed disorders. 
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Research variables 
Independent variable 
Independent variables in this research are type of antibiotics, i.e. 3
rd
 generation cephalosporin 
antibiotic single or combination 3
rd
 cephalosporin with macrolide. 
Dependent variable 
Dependent variable in this study which will be examined the results are leukocyte, body 
temperature, shortness of breath, and length of stay. 
Confounding variable 
The confounding variables in this study are patient accompanying diseases and the presence of 
drug related problems that can interfere with the effectiveness of treatment. 
 
Data Analysis 
Characteristics test of each antibiotic using univariate analysis. The first requirement for the 
comparative test of antibiotics on the outcome of therapy is to test the data normality first to ensure the 
value of each data distribution of each group by Shapiro Wilk method because the sample is below 50 
data. 
Results of temperature normality test in 3
rd
 generation cephalosporin is p = 0.254 while 
combination of 3
rd
 generation cephalosporin and macrolide that is p = 0.311. The test indicates that the 
distribution of data is normal with p > 0.05 so that this comparative statistic test using parametric test 
with T-test paired method for interval data with p > 0.,05. 
Results of shortness of breath normality test in both of groups is p = 0.001. The test indicates 
that the distribution of data is abnormal with p < 0.05 so this comparative statistic test using non 
parametric test with Fisher’s method for nominal data with p < 0.05. 
Results of leucocyte count normality test in 3
rd
 generation cephalosporin is p = 0.982 while 
combination groups is p = 0.163. The test indicates that the distribution of data is normal with p > 0,05 
so this comparative statistic test using parametric test with T-test paired method for interval data with 
p > 0.05. 
Results of length of stay normality test in 3
rd
 generation cephalosporin is p = 0.001 while 
combination groups is p = 0.039. The test indicates that the distribution of data is abnormal with p < 
0,05 so this comparative statistic test using non parametic test with Mann-Whitney method for interval 
data with p < 0,05 (Ethical Number: 011710140). 
 
RESULTS AND DISCUSSION 
Patient characteristics 
Subjects in this study included the gender and age of adult CAP patients. A total of 37 divided 
into two groups namely 3
rd
 generation cephalosporins as many as 24 patients, and a combination of 
cephalosporins 3
rd
 generation and macrolide as many as 13 patients. Characteristics of patients 
receiving antibiotics can be seen at Table I. 
Table I. Characteristics of CAP patients admitted to hospital at PKU Muhammadiyah Yogyakarta who 
received antibiotics 
Characteristics 
 
Total (%) Mean ± SD 
3rd generation 
cephalosporins 
3rd generation cephalosporins & 
macrolide 
P 
   n (%) n (%)  
Sex  
Male 26 (70.3) - 18 (69.2) 8 (30.8) 
0.399 
Female 11 (29.7) 6 (54.5) 5 (45.5) 
Ages  
18-59 years old 18 (48.6) 57.49 ± 15.12 12 (66.7) 6 (33.3) 
0.826 
> 59 years old 19 (51.4) 12 (63.2) 7 (36.8) 
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Based on sex, 70.3% is dominated by men compared to women who only 29.7%. Similar to 
previous research of Hariri et al. (2017) male patients with adult CAP inclusion were 55% greater than 
female patients at 45%. Similarly, research of Sajinadiyasa, et al. (2011) where the largest population 
is men with 52.72% compared to women who only 47, 27%. And 64% of men dominate the adult CAP 
population than women who are only 36% (Zhong, et al., 2014). The greater risk of community 
pneumonia in men is greater because of the greater incidence of cigarette smoking for adult males, it 
also increases the risk of lung disease such as bronchitis or community pneumonia (Elfidasari, et al., 
2013).  
Based on age in this study shows that 51.4% is dominated by age group above 59 years, while 
the remaining is dominated by age group of 18 - 59 years of 48.6% with an average yield of 57.49 
years. Similar to subsequent studies, patients over the age of 60 years also dominate the CAP subject 
of inpatients (Pahriyani, et al., 2015). But contrast to research Sajinadiyasa, et al. (2011) of 53.3% is 
more dominated by the age group span of under 60 years and only 46.7% in the age group above 60 
years. According to Prince (2006), immunity in maintaining the body will decline with age that begins 
when it has stepped on 50 years and above, it is possible that the number of patients over 50 years 
affected by community pneumonia. It is above shows that there is no significant difference between 
men and women, as well as between the ages of 18-59 with> 59 years. 
 
Difference effectiveness of the antibiotics to temperature outcome 
This aims to determine differences in clinical changes of CAP patients after 3
rd
 generation 
cephalosporins compared to combination of 3
rd
 generation cephalosporins and macrolides at the 
hospitalization of PKU Muhammadiyah Yogyakarta hospital. The clinical parameters of the patients 
measured before and after antibiotics are temperature which is an indication of infection in the body 
and as a target for the patient's clinical condition (Bradley, et al., 2011). 
CAP patient temperature measurements were performed when the patient was admitted to 
hospital with CAP diagnosis and had not received antibiotics and further temperature measurements 
were performed at the time of antibiotic therapy over 72 hours. 
 
Table. II Descriptive analysis and 3
rd
 generation cephalosporins effectivity differences compared 
to 3
rd
 generation cephalosporins and macrolides to temperature outcomes 
Groups Mean ± SD Difference ± SD Range P P 
The 
3rd
 generation cephalosporin (n = 23) 
0.001* 
Temperature before therapy 37.2 ± 0.87 0.79 ± 1.06 0.9 (1.24 – 0.24) 0.001* 
Temperature after therapy 36.4 ± 0.99 
The 
3rd
 generation cephalosporin and macrolide (n = 14) 
Temperature before therapy 37.1 ± 0.97 0.65 ± 1.07 1.30 (1.30-0.003) 0.049* 
Temperature after therapy 36.4 ± 0.35 
*t-test paired  
Table.II shows two descriptives and t-test paired analyzes. Descriptive analysis showed that 
each 3
rd
 generation cephalosporins (single) and 3
rd
 generation cephalosporin and macrolide 
(combination) had an average difference and the difference in decreasing CAP patient temperature. 
Difference in temperature of single group had 0.79 
o
c with standard 1.06 intake while the difference in 
temperature drop in combination groups had 0.65 
o
c with standard deviation 1.30. Judging from the 
difference in temperature decrease for both groups above, single group was higher in decreasing 
temperature compared to the combination groups. As for the range of temperature drop, the 
combination groups with a range of 1.30 
o
c is greater than the single group with a range of 0.9 
o
c. The 
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value is obtained from the maximum value of CAP patient temperature minus the minimum value of 
CAP patient's body temperature. 
The result paired T-test analysis on single group with p = 0.001 showed that there was a 
significant difference between patient's temperature before and after single treatment because p < 0.05 
similarly in combination groups with p = 0.049 showed that there was a significant difference between 
body temperature of patients before and after combination treatment because p < 0.05. It is above 
shows that there is a significant difference between the use of 3
rd
 generation cephalosporins and 3
rd
 
generation cephalosporins and macrolides againts temperature before and after therapy. 
 
Difference effectiveness of the antibiotic to shortness of breath outcomes 
This aims to know the difference of 3
rd
 generation cephalosporin compared to 3
rd
 generation 
cephalosporin and macrolide to shortness of breath of adult CAP patient at hospitalization of PKU 
Muhammadiyah Yogyakarta hospital. Parameters measured at the time the patient has been out of the 
hospital the patient is still complaining of shortness of breath or not. Shortness of breath is an 
indication of the presence of infection in the body and as a target stability of the patient's clinical 
condition (Bradley, et al., 2011). 
Table III. Differences in effectiveness of 3
rd
 generation cephalosporins compared to 3
rd
 
generation cephalosporins and macrolides againts shortness of breath of 
adult CAP 
Groups Shortness Of Breath P (p< 0.05) 
 Yes (%) No (%)  
3rd
 generation 
cephalosporins 
4 (16.7) 20 (83.3) 0638 * 
  
3rd
 generation 
cephalosporins and 
macrolide 
1 (7.7) 12 (92.3) 
Total (%)    5 (13.5)    32 (86.5)   37 (100) 
*Fisher’s    
Table III shows results of fisher's test (p = 0.638), the results show  p > 0.05 there isno 
significant difference between the 3
rd
 generation cephalosporin versus 3
rd
 generation 
cephalosporins and macrolides againts shortness of breath therapy in adult CAP patients who 
are hospitalized. 
 
Difference effectiveness of the antibiotic to leucocyte outcome 
Leukocyte measurements were performed twice when patient was admitted to the hospital with 
CAP diagnosis before receiving antibiotic therapy and 72 hours after patient received antibiotic 
therapy. For statistical analysis test results can be seen in Table IV below. 
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Table IV. Descriptive analysis and difference in effectiveness of 3
rd
 generation cephalosporins  
compared to 3
rd
 generation cephalosporins and macrolides against leukocyte 
Groups 
 
Mean ± SD Difference ± 
SD 
Range P P 
      
3
rd
 generation cephalosporin (n = 23) 
0.001* 
Before therapy  14.2 ± 2.92 4.80 ± 3.92 3.31 (6.45 – 3.14) 0.001* 
After therapy  9.40 ± 2.74 
3
rd
 generation cephalosporin and makrolida (n = 14) 
Before therapy  16.48 ± 4.04 5.43 ± 4.27 5.17 (8.02 – 2.85) 0.001* 
After therapy  11 ± 3.52 
*t-test paired  
Table IV. shows that the leukocyte difference decrease on combination with 3
rd
 generation 
cephalosporins and macrolides was greater with a decrease of 5.43 x 10
3
 / mm
3
 and deviation standard 
of 4.27 compared to 3
rd
 generation cephalosporins was only 4.8 x 10
3
 / mm
3
 and deviation standard 
4.27. Furthermore, for the decrease range of leukocyte numbers, 3
rd
 generation cephalosporins and 
macrolides with a range of 5.17 x 10
3
 / mm
3
 is greater than the 3
rd
 generation cephalosporin with a 
range of 3.31 x 10
3
 / mm
3
. The range value is obtained from maximum leukocyte value minus 
leukocyte value of the CAP patient. 
The result of paired t-test for 3
rd
 generation cephalosporin with value (p = 0,001) while the 
combination group of 3
rd
 generation cephalosporin and macrolide with value (p = 0,001) statistically 
showed a significant difference between the use of 
3rd
 generation cephalosporin and a combination of 
3rd
 generation cephalosporins and macrolides againts leukocyte reduction in CAP patients. It is above 
shows that there is a significant difference between the use of 3
rd
 generation cephalosporins and 3
rd
 
generation cephalosporins and macrolides againts leucocyte before and after therapy. 
In a fact in the use of combination of 3
rd
 generation cephalosporins and macrolides, which 
macrolides can help decrease the production of interleukin-8 (IL-8) and tumor necrosis factor-alpha 
(TNF-α) in pneumonia patients (Takizawa, et al., 1997). Gram-negative bacteria in their cell 
membrane structure are composed of lipopolysaccharide endotoxin (LPS). When these bacteria infect 
the body, non-specific defense systems such as macrophages will recognize LPS from gram-negative 
bacteria, the presence of bonds between macrophages with LPS will cause macrophages to express a 
number of proinflammatory cytokines IL-8 and TNF-α. Activation of these cytokines in excessive 
amounts automatically leads to worse patient prognosis such as Systemic Inflammatory response 
syndrome (SIRS) as well as sepsis (Baratawidjaja, et al, 2014). 
 
Difference effectiveness of the antibiotic to length of stay 
This aims to determine the difference of 3
rd
 generation cephalosporins compared to 3
rd
 
generation cephalosporins and macrolides to length of stay of adult CAP patients at the hospitalization 
of PKU Muhammadiyah Yogyakarta hospital. Parameters were measured using a count of days during 
which patients were admitted to hospital. 
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Table.V Differences in effectiveness of 3
rd
 generation cephalosporins compared to 3
rd
 generation 
cephalosporins and macrolides on the length of stay in adult CAP patients 
Length of stay Antibiotics P 
 
3
rd
 generation 
cephalosporins 
3
rd
 generation 
cephalosporins 
and macrolides 
 
The Mean ± SD 5.88 ± 3.261 5.00 ± 1.826 
0.435* Median 5.00 4.00 
Range 15 6 
*Mann-whitney       
Table.V shows a Mann-Whitney analysis with a value (p = 0.435), becaused p > 0.05 its shows 
that there is no significant difference between the use of a 3
rd
 generation cephalosporin single 
antibiotic compared to a combination of 3
rd
 generation cephalosporins and macrolides the long-term 
outcome of hospitalization in adult CAP patients statistically. However, mean ± SD results indicate 
that the use of 3
rd
 generation cephalosporins with macrolides is 0.88 days longer in hospital than a 3
rd
 
generation cephalosporins although not significantly different. 
This is similar with research of Sajinadiyasa, et. al. (2011) used a inpaired T-test of the Mann-
Whitney method where the average length of stay of combined antibiotic use had 8.58 days with a 
deviation standard of 0.917 (8.58 ± 0.917) while the use of a single antibiotic had 14, 80 days with 
deviation standard of 4.258 (14.80 ± 4.258), its indicated that combination antibiotic usage had 
average length of stay faster than single antibiotic with p value = 0.075 (p>0.05) which mean there 
was not significant difference between both of these antibiotics. Similar with Trowbridge, et. al. 
(2002) where the use of combination 3
rd
 generation cephalosporin and macrolides (azithromycin) had a 
4.6 day treatment time with a deviation  standard of 0.34 (4.6 ± 0.46) while 3
rd
 generation 
cephalosporins( ceftriaxon) had a long treatment time of 6.3 days with a deviation standard of 0.53 
(6.3 ± 0.53) having a significant relationship with p <0.05. This possibility is triggered by a lack of 
patient suggestion to heal on the use of this single antibiotic. 
The treatment between combination 3
rd
 generation cephalosporins and macrolides was more 
effective in reducing mortality and length of stay than a single 3
rd
 generation cephalosporin for CAP 
patients with p = 0.03 97% CI (Caballero and Rello, 2011). Administration of macrolides in CAP 
patients during the first 24 hours will inhibit the occurrence of inflammation in the early stages of the 
disease. This macrolides can shortens the length of stay admitted to the hospital after 24 hours. This 
proves that macrolides can inhibit the production of interleukins and may reduce the proinflammatory 
agent resulting from bacterial production (Culic, O., et al., 2002). 
Treatments with beta-lactamase and macrolides may reduce risk of death higher than 3
rd
 
generation cephalosporins alone, but both in a double-blind Random Controlled Trials study where 
treatments combination beta-lactamase and macrolides and  beta lactamase alone is needed for CAP 
patients (Niet, et al., 2014). In contrast to a study conducted by Health Quality Ontario (2013) there 
was no significant difference in mortality reduction or treatment failure in inpatient CAP patients 
receiving either combination or single antibiotic therapy. 
 
LIMITATIONS OF THE RESEARCH 
The researchers excluded a large number of subjects due to the lack of re-leukocyte tests in 
patients, which resulted in the number of patients taken as respondents too few. The subject of CAP is 
considered equal in terms of severity (mild, moderate, severe). 
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CONCLUSION 
Comparison of therapeutic efficacy of 3
rd 
generation cephalosporins alone againts 3
rd
 generation 
cephalosporins and macrolides showed significant difference on temperature and leukocyte with p 
<0,05. While the effectiveness of 3
rd
 generation cephalosporins alone againts 3
rd
 generation 
cephalosporins and macrolides showed no significant difference shortness of  breath and length of stay 
with p > 0,05. 
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